New York, US – August 24, 2018 – Creative Biolabs, a dynamic and professional biotech company located in New York, now provides world-leading dendritic cell vaccine development services as part of DC-based immunotherapy to worldwide clients, aiming to speed up the development projects for academic and clinical purposes.
Owing to their powerful antigen-presenting functions for the induction of antigen-specific T cell response, dendritic cells (DCs) become the crucial component of vaccination and DC vaccine and are introduced as a new therapeutic strategy in cancer patients, such as CAR-DC immunotherapy.
According to the scientist in Creative Biolabs, DC-based immunotherapy is more attractive for its safety and efficacy to promote anti-tumor immune responses and prolonged survival of cancer patients compared to the conventional treatment. Several ways are available to employ DC-based immunotherapy approaches. First, direct targeting/stimulating of the DCs in vivo can be applied to accentuate their anti-cancer phenotype. Second, DCs can be stimulated ex vivo and infused back into the host for carrying out anti-cancer effector functions.
“The engineered DCs (Dendritic Cell) in Creative Biolabs can raise specific anti-tumor immune response, recruit and stimulate unique NK cells, and produce plenty of key chemokines to attract other immune cells, which help contribute to combined activation of T-helper cells and stimulation of higher numbers of killer T-cells. Notably, we are so proud that our potent DCs can be manufactured in only three days.”
Ph.D. scientific team in Creative Biolabs is promised to guarantee the highest success rate of each project. With good reputation over years in the field of immunotherapy all over the world, we are more than happy to share our technologies, platforms, and experience to facilitate your projects.
About Creative Biolabs
As a global company, Creative Biolabs have more than 200 talented and well-trained scientists located in different continents working closely with partners from the entire world to develop and produce medicines of tomorrow. Specifically, we are the established leading expert in TCR and CAR T&NK cell immune therapy development, as we offer the one-stop custom services that cover the entire new drug development pipeline. Additionally, we also offer an exclusive line of ready-to-use TCR and CAR T&NK cell construction products, such as virus packaging, purification, expansion and titer determination kits. Furthermore, we have built up a unique unparalleled CAR construction and production platform for all four CAR generations.
Media Contact
Company Name: Creative Biolabs
Contact Person: Bella Smith
Email: Send Email
Phone: 1-631-619-7922
Address:45-1 Ramsey Road
City: Shirley
State: New York
Country: United States
Website: https://www.creative-biolabs.com/car-t